



Notice of Results

February 9, 2024 1:05 PM EST

```
var w=window;[w.performance][w.msPerformance][w.webkitPerformance]{var d=document;AKSB=w.AKSB||{};AKSB.q=AKSB.q||{};AKSB.mark=AKSB.mark||function(e,_){{AKSB.q.push(["mark",e,_(new Date).getTime()]);AKSB.measure=AKSB.measure||function(e,_){{AKSB.q.push(["measure",e,_(new Date).getTime()]);AKSB.done=AKSB.done||function(e){AKSB.q.push(["done",e]);AKSB.mark(["firstbyte",_(new Date).getTime()]);AKSB.prof={custid:"792678",ustr:"original","clientid":"3",ghostip:"23.36.67.195",ip6:false,pct:"10",clientip:"52.200.45.141",requestid:"f24a66e",region:"36639",protocol:"bliver",akM:"dscs",akN:"ae",akTT:"O",akTX:"1",akTL:"f24a66e",ai:"501146",ra:"false",pmgn:"",pmgi:"",pmp:"",qc:""},function(e){var _=d.createElement("script");_._async="async";_._src=e;var t=d.getElementsByTagName("script"),t=[(t.length-1),t.parentNode.insertBefore(_),t].parentNode.insertBefore(_)}]}]}(https://ds-aksb-a.akamaihd.net/aksb.min.js)
RNS Number : 6743C
MaxCyte, Inc.
09 February 2024
```

MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences

ROCKVILLE, MD, February 9, 2024 - MaxCyte, Inc., (NASDAQ: MXT; LSE: MXT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced that it will release financial results for the fourth quarter and full year 2023 after the U.S. market close on Tuesday, March 12th, 2024. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

Earnings Conference Call Details

Investors interested in listening to the conference call are required to [register online](#). It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the "Events" section of the MaxCyte website at <https://investors.maxcyte.com/>.

Company management will also participate in the following investor conferences:

- 11th Annual BTG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Tuesday, February 13th
- 44th Annual Cowen Healthcare Conference
Tuesday, March 5th at 9:10 a.m. ET

A live and archived webcast of the Cowen presentation will be available on the "Event" section of the MaxCyte investor relations website at <https://investors.maxcyte.com/>.

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transaction workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on [X](#) (formerly Twitter) and [LinkedIn](#).

MaxCyte Contacts:

US IR Adviser

Gilmarin Group

David Deuchler, CFA

+1 415-937-5400

ir@maxcyte.com

US Media Relations

Spectrum Seismic Collaborative

Valerie Enes

+1 408-497-8568

venes@spectrumscience.com

Nominated Adviser and Joint Corporate Broker

Pannure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

+44 (0)20 7886 2500

UK IR Adviser

ICR Consultam

Mary-Jane Elliott

Chris Welsh

+44 (0)203 709 5700

maxcyte@consultam-comms.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rm@lseg.com or visit www.lseg.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORUKAARSUURAR